For example, about 35% of the POLE mutation subgroup tumors are accompanied by P53 mutations and still have a better prognosis than other genomic subgroups, which is also the reason that POLE mutation analysis is performed in preference to P53 mutation analysis in the ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer) classifier (33, 34). The gene discussed is TP53; the disease is endometrial cancer.